SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 66 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $3,298,000 | +91.3% | 240,403 | 0.0% | 0.48% | +106.5% |
Q4 2016 | $1,724,000 | -52.7% | 240,403 | 0.0% | 0.23% | -42.3% |
Q3 2016 | $3,645,000 | +72.6% | 240,403 | +12.1% | 0.40% | +34.4% |
Q2 2016 | $2,112,000 | -26.1% | 214,419 | 0.0% | 0.30% | -30.5% |
Q1 2016 | $2,856,000 | – | 214,419 | – | 0.43% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |